Jun 4, 2025 | Foods, On Demand Webinar
Many people have difficulty understanding the Nutrition Facts label, especially with regards to properly interpreting and using the information about serving sizes and the percent Daily Values. This webinar will clear up some of the confusion about these and other labeling issues. This webinar will also discuss some of the science that went into developing the Nutrition Facts label and explain why FDA decided to update and modernize the label in 2016. By attending this webinar, you will become a more knowledgeable label reader.
May 21, 2025 | Dietary Supplements, On Demand Webinar
Since the FDA’s dietary supplement cGMP regulations (21 CFR Part 111) were published, specifications and testing have been consistently one of the most frequently cited FDA observations. Specifically, industry continues to face challenges in complying with the specification and testing requirements for dietary supplement components.
Apr 23, 2025 | Foods, On Demand Webinar
Simply put, Artificial Intelligence (AI) is the ability of a computer to perform tasks commonly associated with humans. In the area of food safety and food regulatory compliance, there are many tasks in which AI applications can be used, some more advanced than others.
Mar 18, 2025 | Dietary Supplements, Drugs, Foods, Medical Devices, On Demand Webinar
Foreign entities who operate in US FDA-regulated industries must have an appointed FDA US agent before they can import products into the US. At a minimum these FDA US agents provide the most basic of required services. However, agents with relevant experience and knowledge can provide much more.
Nov 8, 2024 | Cosmetics, Dietary Supplements, Drugs, Foods, Medical Devices, On Demand Webinar
This webinar will help you understand in detail Computer System Validation (CSV) and how to apply the System Development Life Cycle (SDLC) Methodology
Oct 16, 2024 | Drugs, On Demand Webinar
Good ANDA Submission Practices Proactive Planning for the Best Possible Outcomes Presented by Radhika Rajagopalan, Ph.D., EAS Independent Consultant FDA recent draft and final guidance documents related to generic drugs indicate the Agency’s thinking with regards to...
